Medicine:Time delay toxin activation
From HandWiki
Time Delay Toxin Activation (TDTA) belongs to a class of chemotherapy drugs known as High Specificity Anticancer Agents. This is a process for manufacturing and administering chemotherapy drugs in a nontoxic, proto-drug form. Then, after a time delay to allow for concentration in the target cancer or invasive tissues or cells, the non-toxic drug is then modified by an activation drug to selectively provide toxic levels of a pharmacologically active agent to the target issue. This minimizes the toxicity to healthy cells, reducing the adverse side-effects of chemotherapy.
This idea was first proposed by Dr. Evan Harris Walker in 1980.
References
- "US Patent Office application number 20040192578". http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220040192578%22.PGNR.&OS=DN/20040192578&RS=DN/20040192578. Retrieved February 2, 2006.
- "High specificity anticancer agents". USPTO Full text patent database. http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=/netahtml/search-bool.html&r=1&f=G&l=50&co1=AND&d=ptxt&s1=6,767,919.WKU.&OS=PN/6,767,919&RS=PN/6,767,919. Retrieved January 29, 2006.
![]() | Original source: https://en.wikipedia.org/wiki/Time delay toxin activation.
Read more |